Agenus Inc. Common Stock AGEN
i
Market dataready · fetched 2026-11-04T08:54:16.057Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T21:00:06.101438886Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-04T08:54:15.612845+00:00
Agenus Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 5.13 | 192.3% | 28.7% | |||
| 25Δ | 8.30 | 125.1% | 28.0% | 5.53 | 173.4% | 23.6% |
| 30Δ | 8.00 | 129.9% | 24.4% | 5.93 | 154.4% | 18.5% |
| 35Δ | 7.77 | 138.6% | 22.7% | 6.19 | 145.7% | 15.7% |
| 40Δ | 7.54 | 147.3% | 21.0% | 6.43 | 139.3% | 13.5% |
| 45Δ | 7.31 | 155.9% | 19.2% | 6.67 | 132.9% | 11.3% |
| 50Δ | 7.08 | 164.6% | 17.5% | 6.91 | 126.4% | 9.1% |
| 55Δ | 6.83 | 158.6% | 15.0% | 7.10 | 120.1% | 7.5% |
| 60Δ | 6.58 | 145.1% | 11.9% | 7.27 | 113.7% | 6.4% |
| 65Δ | 6.33 | 131.6% | 8.9% | 7.43 | 107.4% | 5.2% |
| 70Δ | 6.08 | 118.1% | 5.9% | 7.60 | 101.0% | 4.1% |
| 75Δ | 5.83 | 113.6% | 4.3% | 7.77 | 94.6% | 3.0% |
| 80Δ | 5.57 | 113.3% | 3.3% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.13
- IV
- 192.3%
- B/E move
- 28.7%
25Δ
- Pseudo strike
- 8.30
- IV
- 125.1%
- B/E move
- 28.0%
- Pseudo strike
- 5.53
- IV
- 173.4%
- B/E move
- 23.6%
30Δ
- Pseudo strike
- 8.00
- IV
- 129.9%
- B/E move
- 24.4%
- Pseudo strike
- 5.93
- IV
- 154.4%
- B/E move
- 18.5%
35Δ
- Pseudo strike
- 7.77
- IV
- 138.6%
- B/E move
- 22.7%
- Pseudo strike
- 6.19
- IV
- 145.7%
- B/E move
- 15.7%
40Δ
- Pseudo strike
- 7.54
- IV
- 147.3%
- B/E move
- 21.0%
- Pseudo strike
- 6.43
- IV
- 139.3%
- B/E move
- 13.5%
45Δ
- Pseudo strike
- 7.31
- IV
- 155.9%
- B/E move
- 19.2%
- Pseudo strike
- 6.67
- IV
- 132.9%
- B/E move
- 11.3%
50Δ
- Pseudo strike
- 7.08
- IV
- 164.6%
- B/E move
- 17.5%
- Pseudo strike
- 6.91
- IV
- 126.4%
- B/E move
- 9.1%
55Δ
- Pseudo strike
- 6.83
- IV
- 158.6%
- B/E move
- 15.0%
- Pseudo strike
- 7.10
- IV
- 120.1%
- B/E move
- 7.5%
60Δ
- Pseudo strike
- 6.58
- IV
- 145.1%
- B/E move
- 11.9%
- Pseudo strike
- 7.27
- IV
- 113.7%
- B/E move
- 6.4%
65Δ
- Pseudo strike
- 6.33
- IV
- 131.6%
- B/E move
- 8.9%
- Pseudo strike
- 7.43
- IV
- 107.4%
- B/E move
- 5.2%
70Δ
- Pseudo strike
- 6.08
- IV
- 118.1%
- B/E move
- 5.9%
- Pseudo strike
- 7.60
- IV
- 101.0%
- B/E move
- 4.1%
75Δ
- Pseudo strike
- 5.83
- IV
- 113.6%
- B/E move
- 4.3%
- Pseudo strike
- 7.77
- IV
- 94.6%
- B/E move
- 3.0%
80Δ
- Pseudo strike
- 5.57
- IV
- 113.3%
- B/E move
- 3.3%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 113.99% | |
| 103.44% | |
| 121.60% | |
| 137.83% | |
| 120.03% | |
| 130.68% | |
| 108.31% | |
| 182.95% | |
| 166.24% | |
| 150.79% | |
| 126.56% | |
| 105.63% | |
| 106.18% | |
| 104.86% | |
| 105.07% | |
| 113.14% | |
| 104.20% | |
| 115.29% | |
| 106.76% | |
| 100.51% | |
| 97.08% | |
| 114.46% | |
| 126.71% | |
| 116.05% | |
| 123.96% | |
| 129.63% | |
| 134.83% | |
| 148.50% | |
| 163.51% | |
| 99.94% | |
| 115.18% | |
| 97.57% | |
| 95.16% | |
| 110.71% | |
| 102.83% | |
| 104.03% | |
| 93.62% | |
| 100.01% | |
| 92.54% | |
| 97.19% | |
| 91.44% | |
| 103.25% | |
| 97.47% | |
| 99.84% | |
| 97.63% | |
| 106.88% | |
| 99.31% | |
| 138.60% | |
| 97.36% | |
| 95.88% | |
| 99.87% | |
| 99.50% | |
| 94.49% | |
| 102.61% | |
| 105.88% | |
| 105.08% | |
| 114.86% |
Biotechnology
AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, is dedicated to drug discovery and development in the field of cellular metabolism and adjacent areas of biology. The…
More →AKTS
Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures and sells radio frequency (RF) filter products for the wireless mobile device…
More →AKTX
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve…
More →ALDX
Aldeyra Therapeutics, Inc., a biotechnology company, develops and markets drugs for immune-mediated systemic and eye diseases. The company is headquartered in Lexington,…
More →ALEC
Alector, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of neurodegenerative diseases. The company is headquartered in South San Francisco,…
More →ALLO
Description unavailable
More →